Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 9/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20576681 | 0.83 | JAK2 (0.53) | PRCPJAK2JAK3SMN1; SMN2 | |
| SCHEMBL20576692 | 0.79 | NR3C2 (0.46) | PRCPNUDT1 | |
| SCHEMBL4580268 | 0.76 | NUDT1 (0.46) | NUDT1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22444791 | 0.73 | CYP17A1 (0.33) | PRCPTSHR | |
| SCHEMBL29649095 | 0.73 | CYP17A1 (0.33) | PRCPTSHR | |
| SCHEMBL22444806 | 0.73 | CYP17A1 (0.33) | PRCPTSHR | |
| SCHEMBL83400 | 0.72 | CUL4A (0.38) | PRCPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22327900 | 0.72 | NEK1 (0.44) | PRCP | |
| SCHEMBL24654724 | 0.72 | PSEN1 (0.39) | PRCPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16240795 | 0.71 | NPC1 (0.48) | NUDT1CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180346451-A1 | TRK INHIBITION | NANTBIO, INC. | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346451-A1 | TRK INHIBITION | NGFR, NGF, NTRK1 | PRCP 3333/4885NUDT1 585/4885PSEN1 2950/4885 |
| US-10738033-B2 | Trk inhibition | NGF, NGFR, NTRK2 | PRCP 3369/4885NUDT1 994/4885PSEN1 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.